EVO756

Small molecule

Earlyevidence

Evidence outlook

Migraine: mid-stage studies underway, no completed readout

In Migraine, Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. Studies in other indications have read out; see the trials and Regulatory events below.

Also in development:Chronic Inducible Urticaria · Phase 2

Development in Atopic Dermatitis stopped (2026-09-08) after a negative readout. Source

Company guidance: data expected in 2027 (Evommune, 6 Aug 2026). “We have also initiated a Phase 2b trial of EVO756 in migraine prophylaxis in July 2026 and we expect to report initial results in 2027.” Source ↗

Company guidance: topline data expected 2H 2027 (Evommune, 12 Nov 2026). “Phase 2b Dose-Ranging Trial in Migraine Prophylaxis Top-line Data Expected in 2H 2027 © Evommune, Inc. BL = Baseline; CFB = change from baseline; MMD = monthly migraine days; MHD = monthly headache days; QoL = quality of life BL Adults with Refractory Migraine ≥6 Days/Month (N ≈ 330) Screening Enrollment W12 EVO756, 25mg BID EVO756, 50mg BID Placebo Randomized, Double-Blind, Placebo-Controlled Trial Primary Endpoint Mean CFB in MMD Key Secondary Endpoints ≥50%, ≥75% reduction in MMD CFB in MHDs CFB in monthly acute migraine medication use Exploratory Endpoints Patient subtyping Changes in biomarkers Change in migraine-specific QoL” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (4)
Chronic Inducible Urticaria
Migraine
Other / comorbidity
NCT06873516 · Evommune, Inc.
2025-03-20 – 2026-06-05 · Chronic Spontaneous Urticaria
What this study did

Competitive landscape

This drug's own stage for Chronic Inducible Urticaria: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
EVO756: this drugPhase 2Small moleculeMRGPRX2not yet gradedNo reviewed efficacy summary in this indication
BarzolvolimabPhase 3Monoclonal antibodyKITnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow EVO756 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
October 2027 (1)
Phase 2MigraineRecruiting
Est. primary completion 2027-10 · NCT07616128 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 September 2026Topline resultPhase 2b of EVO756 in atopic dermatitis did not meet its primary endpoint
Evommune · Source ↗
29 June 2026Topline resultPhase 2b of EVO756 in chronic spontaneous urticaria did not meet its primary endpoint
Evommune · Source ↗